Extracellular vesicles from SB431542-conditioned human adipose-derived stem cells enhance in vitro and in vivo osteogenesis via a miR-20a-5p-BAMBI-BMP/canonical Wnt signaling axis.
Huber J., Longaker MT., Quarto N.
Animal Study, published in Stem Cells Transl Med (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Stem Cells Transl Med (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42178698
- PMCID
- PMC13199063
- DOI
- 10.1093/stcltm/szag026
Abstract (original English)
Background Critical-sized bone defects resulting from tumors, trauma, or surgery present a significant clinical challenge due to its poor self-regenerating capabilities and limited therapeutic options. Mesenchymal stem cells (MSCs) have shown promise in bone regeneration, possibly mediated through their secretion of bioactive factors rather than direct engraftment and differentiation. MSC-derived extracellular vesicles (EVs) deliver micro-RNAs (miRs), proteins, and lipids that may modulate bone regeneration. Methods EVs were isolated by differential ultracentrifugation from osteogenically induced human adipose-derived stem cells (hASCs), treated with or without the small molecule SB431542, an inhibitor of TGFβ signaling (EV-hASCs[-/+]SB). EVs were characterized using western blot and nanoparticle tracking analysis. hASCs were cultured with EV-hASCs[-/+]SBs to assess bone regeneration in vitro. Bone regeneration was assessed in vivo in calvarial defects treated with (EV-hASCs[-/+]SB). EV "cargo" was analyzed for miR-content. Results Enhanced osteogenesis is shown in vitro and in vivo upon treatment with EV-hASCs[+]SB. EV-hASCs[+]SB-enriched-miR-20a-5p was identified as a modulating factor in osteogenesis, silencing BAMBI and enhancing early downstream phosphorylation of SMAD1/5 and late activation of β-catenin in hASCs undergoing osteogenic differentiation, targets of bone morph
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.